ATE399768T1 - Indazolderivate und ihre verwendung als crf antagonisten - Google Patents

Indazolderivate und ihre verwendung als crf antagonisten

Info

Publication number
ATE399768T1
ATE399768T1 AT03776916T AT03776916T ATE399768T1 AT E399768 T1 ATE399768 T1 AT E399768T1 AT 03776916 T AT03776916 T AT 03776916T AT 03776916 T AT03776916 T AT 03776916T AT E399768 T1 ATE399768 T1 AT E399768T1
Authority
AT
Austria
Prior art keywords
crf antagonists
indazol
derivatives
indazol derivatives
crf
Prior art date
Application number
AT03776916T
Other languages
English (en)
Inventor
Richard Cournoyer
David Loughhead
Counde O'yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE399768T1 publication Critical patent/ATE399768T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03776916T 2002-12-02 2003-11-24 Indazolderivate und ihre verwendung als crf antagonisten ATE399768T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43016802P 2002-12-02 2002-12-02

Publications (1)

Publication Number Publication Date
ATE399768T1 true ATE399768T1 (de) 2008-07-15

Family

ID=32469420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03776916T ATE399768T1 (de) 2002-12-02 2003-11-24 Indazolderivate und ihre verwendung als crf antagonisten

Country Status (21)

Country Link
US (2) US7214699B2 (de)
EP (1) EP1569911B1 (de)
JP (1) JP4401298B2 (de)
KR (1) KR100761562B1 (de)
CN (1) CN100439341C (de)
AR (1) AR042148A1 (de)
AT (1) ATE399768T1 (de)
AU (1) AU2003286180B2 (de)
BR (1) BR0316950A (de)
CA (1) CA2507074A1 (de)
DE (1) DE60321958D1 (de)
ES (1) ES2309368T3 (de)
GT (1) GT200300263A (de)
MX (1) MXPA05005794A (de)
PA (1) PA8589601A1 (de)
PE (1) PE20040764A1 (de)
PL (1) PL377609A1 (de)
RU (1) RU2341518C2 (de)
TW (1) TW200418816A (de)
UY (1) UY28105A1 (de)
WO (1) WO2004050634A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004025354D1 (de) * 2003-08-14 2010-03-18 Hoffmann La Roche Gabanerge modulatoren
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
AR050253A1 (es) * 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
AU2005271737A1 (en) * 2004-08-03 2006-02-16 Wyeth Indazoles useful in treating cardiovascular diseases
CN100516049C (zh) * 2004-11-16 2009-07-22 永信药品工业股份有限公司 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CN101466703A (zh) * 2006-04-11 2009-06-24 弗·哈夫曼-拉罗切有限公司 杂环GABA-α亚型选择性受体调节剂
ITMI20062230A1 (it) 2006-11-22 2008-05-23 Acraf Composto 2-alchil-indazolico procedimento per preparalo e composizione farmaceutica che lo comprende
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (de) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2012026511A1 (ja) * 2010-08-27 2012-03-01 協和発酵キリン株式会社 医薬組成物
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
WO2016014904A1 (en) 2014-07-24 2016-01-28 Beta Pharma, Inc. 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
KR101713303B1 (ko) * 2015-12-24 2017-03-07 강원대학교산학협력단 2ｈ-인다졸 유도체의 제조방법
WO2022107064A1 (en) 2020-11-20 2022-05-27 Idemitsu Kosan Co., Ltd. Heterocyclic compound and an organic electroluminescence device comprising the heterocyclic compound
CN113831319A (zh) * 2021-10-19 2021-12-24 北京科技大学 含有大位阻取代基芳基硼酸/硼酸酯的铃木反应方法
KR20230081778A (ko) 2021-11-29 2023-06-08 조이운 VOCs 저감장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005109A (en) * 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
US5712303A (en) * 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5705646A (en) * 1993-09-30 1998-01-06 Pfizer Inc. Substituted pyrazoles as CRF antagonists
US5668145A (en) * 1993-11-12 1997-09-16 Pfizer Inc. Amino-substituted pyrazoles having CRF antagonistic activity
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
US5760225A (en) * 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
PL340753A1 (en) 1997-11-04 2001-02-26 Pfizer Prod Inc Substitution of indazolic bioisoster for cathechol in therapeutically active compounds
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
AU2001234958A1 (en) * 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CA2413002A1 (en) * 2000-06-30 2002-12-19 Banyu Pharmaceutical Co., Ltd. Novel pyrazinone derivatives
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
WO2002016348A1 (en) * 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
JP2005507922A (ja) * 2001-09-19 2005-03-24 ファルマシア・コーポレイション 炎症の治療のための置換されたインダゾール化合物
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
TW200409759A (en) * 2002-09-25 2004-06-16 Wyeth Corp Substituted 4-(indazol-3-yl)phenols

Also Published As

Publication number Publication date
GT200300263A (es) 2004-06-28
UY28105A1 (es) 2004-05-31
JP4401298B2 (ja) 2010-01-20
US20070213373A1 (en) 2007-09-13
RU2341518C2 (ru) 2008-12-20
CN1732158A (zh) 2006-02-08
WO2004050634A1 (en) 2004-06-17
KR100761562B1 (ko) 2007-10-04
EP1569911B1 (de) 2008-07-02
CN100439341C (zh) 2008-12-03
CA2507074A1 (en) 2004-06-17
DE60321958D1 (de) 2008-08-14
AR042148A1 (es) 2005-06-08
AU2003286180B2 (en) 2009-11-12
PL377609A1 (pl) 2006-02-06
AU2003286180A1 (en) 2004-06-23
PE20040764A1 (es) 2004-11-06
TW200418816A (en) 2004-10-01
BR0316950A (pt) 2006-01-17
RU2005120770A (ru) 2006-02-10
US7214699B2 (en) 2007-05-08
US20040110815A1 (en) 2004-06-10
MXPA05005794A (es) 2005-08-16
KR20050084079A (ko) 2005-08-26
JP2006510625A (ja) 2006-03-30
ES2309368T3 (es) 2008-12-16
EP1569911A1 (de) 2005-09-07
PA8589601A1 (es) 2004-09-16

Similar Documents

Publication Publication Date Title
DE60321958D1 (de) Indazolderivate und ihre verwendung als crf antagonisten
DE60316012D1 (de) Purinderivate und ihre verwendung als liganden des cannabinoid rezeptors
DE60314600D1 (de) O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
DE60308387D1 (de) Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
DE60317093D1 (de) Chinolin-; isochinolin- und chinazolinoxyalkylamide und ihre verwendung als fungizide
DE60309874D1 (de) Malonsäuerenitril-verbindungen und ihre verwendung als pestizide
DE60234167D1 (de) Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren
ATE521598T1 (de) 5-phenylthiazol-derivate und ihre verwendung als pi3 kinase inhibitoren
DE60208661D1 (de) Diaminothiazole und ihre verwendung als cyclinabhängige kinase inhibitoren
DE60123210D1 (de) Picolinsäure-derivate und ihre verwendung als fungizide
ATE466012T1 (de) Pyrazolo 3,4-b pyridinverbindungen und ihre verwendung als phosphodiesterase inhibitoren
DE60321558D1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
ATE430729T1 (de) Pyrrol- und pyrazolderivate als potentiatoren von glutamatrezeptoren
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
ATE438395T1 (de) Pyrazolderivate und ihre verwendung als orexin- rezeptor-antagonisten
ATE329906T1 (de) Substituierte 2-anilino-benzimidazole und ihre verwendung als nhe-inhibitoren
ATE321023T1 (de) 3-phenoxy-1-phenyl acetylenderivate und ihre verwendung als herbizide
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
DE50313157D1 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
ATE551329T1 (de) Chinazolinonderivate und deren verwendung als cb- agonisten
ATE384054T1 (de) Substituierte benzoxazinones und ihre verwendung
ATE427748T1 (de) Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
ATE362469T1 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
ATE353083T1 (de) Naphthyridin-derivate und ihre verwendung als fungizide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1569911

Country of ref document: EP

REN Ceased due to non-payment of the annual fee